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Abstract
Depression is the most common psychiatric disorder in coronary artery disease, and it can
worsen cardiac outcomes. Also, cardiac disease predisposes patients to the development of
depression. Assessment of depression is an important part of ongoing patient contacts. It can
be easily done through the regular use of a self-report screening tool and the clinical interview.
Treatment can consist of antidepressant use, psychotherapy and mindfulness-based group
therapy. The antidepressants known as the selective serotonin reuptake inhibitors can gener-
ally be used safely in cardiac patients. They are a mainstay in the treatment of moderate to
severe depression. Individual cognitive-behavioral therapy can treat milder forms of depres-
sion and can augment antidepressant use in more severe cases. Mindfulness-based group
therapy can provide patients with additional means of handling distress while offering social
contact and support, both of which are important in the treatment of depression. The use of
consulting psychiatric services offers the cardiologist a collaborative team approach when
treating patients with depressive illnesses. (Cardiol J 2009; 16, 3: 279–293)
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Case vignette
Steve is a 57 year-old married, white male re-
cently hospitalized for an acute myocardial infarc-
tion (MI). About a week after discharge he saw his
cardiologist. During that visit, he expressed feelings
of sadness and hopelessness. His cardiologist gave
him the Patient Health Questionnaire-9 (PHQ-9),
a nine-item self-report depression questionnaire
[1], on which Steve scored 23, suggesting severe
depressive symptoms. Steve’s cardiologist referred
him for mental health care. The patient was seen
within a week of his referral.
In the initial mental health appointment, the
clinician gathered information about Steve’s current
symptoms, his psychiatric and medical history, his
social and family history, and did a mental status
exam. Steve reported a high level of hopelessness.
He also reported a three-week history of early
morning awakening, low energy, poor appetite, dif-
ficulty concentrating, and irritability. He expressed
decreased interest in activities he used to enjoy, and
had passive suicidal ideation (“I would be better off
dead”). He denied any plan or intent for suicide and
denied any previous attempts. He had no prior psy-
chiatric treatment but noted mild depressive symp-
toms started in adolescence. There was no family
psychiatric history. Steve reported a high level of
stress associated with his job as a supervisor at an
electrical company. He described his work environ-
ment as “demanding and stressful”. He reported
being “obsessive” at his job and not being able to
delegate because he felt he could do a better job.
He could at times lash out at employees. He repor-
ted frequent arguments with his wife, which he at-
tributed to being overwhelmed. He felt unable to
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express his anger without yelling, and had difficul-
ty communicating his thoughts and feelings. Steve
reported a low level of social support, having few
friends and a sedentary lifestyle. He reported a long
history of poor self-image and low self-esteem. He
denied nicotine, alcohol or drug use. On examina-
tion, Steve presented a disheveled appearance, slo-
wed speech, low mood, constricted affect, and te-
arfulness when discussing his health. There were
no hallucinations or delusions, and aside from ne-
gative distortions about his life circumstances, he
was logical in his thinking. He had passive thoughts
of suicide but no active ideation, intent or plans.
Steve met the criteria for a diagnosis of major de-
pression. Treatment is imperative both for the de-
pression and for his cardiac outcome.
Introduction
Stress, anxiety and depression can have signi-
ficant impacts on the heart. They can increase the
likelihood of developing cardiac problems, or wor-
sening cardiac outcomes in patients who already
have cardiac problems. Stress can give rise to arr-
hythmias [2]. Anger can lead to increased risk of
coronary heart disease (CHD) [3–7]. 30–50% of
patients with coronary artery disease (CAD) who
experience mental stress can have transient symp-
tomatic ischemia, left ventricular dysfunction, and
even fatal arrhythmias [8–10]. Heart failure (HF)
patients are at increased risk of MI following epi-
sodes of anger or anxiety [11]. In fact, psychologi-
cal distress confers a greater risk of acute MI than
hypertension, obesity or diabetes [12]. Both depres-
sion and anxiety can increase the risk of CHD in
a graded fashion [13]. There is ample evidence for
the significant prevalence of depression in conge-
stive heart failure (CHF) patients [14, 15]. Depres-
sion increases the risk of developing CHF in pa-
tients with risk factors for it [16], and is a strong
predictor of worsening HF in patients who already
have CHF [17]. Depression can decrease adherence
to medical regimens in cardiac patients [18, 19],
further complicating health issues and contributing
to distress. HF patients with depression are more
likely to die from cardiac events or be medically re-
hospitalized, even when controlling for left ventricular
ejection fraction and brain natriuretic peptide levels
[20]. Morbidity and mortality are known to worsen if
depression occurs after myocardial infarction [21, 22],
and in patients with CHF [20, 23]. Major depression
can worsen cardiac outcomes [14], and depression and
social isolation increase mortality by 2.2–5.4 times
over those without depression [24].
Social factors also play a role in cardiac diffi-
culties. Social isolation and living alone increase
the risk of recurrent coronary events in cardiac pa-
tients, and can lead to worse cardiac outcomes [25].
The fewer support people available to HF patients,
the greater the risk of increased mortality at one
year [26]. Limited social supports can have an
indirect negative impact on cardiac outcomes:
living alone and having fewer supports point
toward the possibility of poorer adherence to
medical regimens, which in turn predicts worse
cardiac outcomes [27].
Stress, anxiety and depression can adversely
impact the heart, but it is also possible that heart pro-
blems give rise to stress, anxiety and depression.
Patients with HF are more likely to develop
depression or experience anxiety and psychosocial
distress as a result of their heart disease. Further,
living with HF challenges coping abilities, and can
lead to diminished job function, worse stamina,
changes in household roles/duties, and more social
isolation. As a result, patients can experience a loss
of control and increased frustration. This can adver-
sely impact cardiac function, and deepen the cycle
of distress and cardiac dysfunction.
It is important to address these issues in the
service of improving cardiac outcomes in cardiac
patients. This paper will focus specifically on de-
pression and interventions for it, as well as descri-
bing a model of collaborative care between the
disciplines of Cardiology and Psychiatry used at the
University of Rochester Medical Center.
Depression and the heart
Major depression is the most common psychia-
tric disorder in coronary artery disease [28]. A stu-
dy of point prevalence of depression in acute MI,
CAD and unstable angina showed a rate of 15–20%
[29]. Another study of CAD patients post-angiogra-
phy showed rates of 16% major depression and 17%
minor depression [30]. CHF patients showed a point
prevalence of about 20% [20, 31]. In a hospitalized
population with CHF, 14% met criteria for major
depression, and 35% showed significant levels of
depression when screening for it using the Beck
Depression Inventory (BDI) [32]. In addition to the
greater likelihood of depression in cardiac patients,
depression is also known to worsen the outcomes
of many general medical conditions. Depression
increases the risk of mortality in nursing home pa-
tients [33], increases morbidity post-stroke [34],
and worsens outcomes in diabetes, cancer, AIDS
and other illnesses [35]. The risk of having an MI
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is increased in patients with at least two weeks of
major depression symptoms [12].
Depression is a systemic disease showing in-
creased neurophysiologic kindling, increase of lo-
cus ceruleus firing rate, causing downstream effects
of increased heart rate, increased blood sugar, in-
creased blood pressure, and decreased gastrointe-
stinal blood flow. Increases in corticotropin rele-
asing factor increases ACTH secretion with the
effect of increasing glucocorticoids, in turn causing
increased lipolysis, increased gluconeogenesis, pro-
teolysis, increased insulin resistance and decreased
inflammation [36]. Physiologically, during depres-
sive episodes, increased platelet aggregation and
thrombus formation occur and there is decreased
heart rate variability [37–39].
The diagnosis of Major Depression per Diagno-
stic and Statistical Manual IV (DSM-IV-TR) [40]
requires ≥ 5 symptoms over a two week period (Ta-
ble 1). However, it can be challenging to detect and
distinguish these symptoms in the midst of many
other medical issues. Complexities of assessment
include: 1) the fallacy of good reasons: “I have good
reasons to be depressed”…”who wouldn’t be de-
pressed?”.”I would be, too, if…”; and 2) multi-de-
termined symptoms — that is, whether the symp-
toms are ‘caused’ by depression or by the co-mor-
bid physical illness (Table 2). Four models have
been examined in an effort to obtain the best dia-
gnostic sensitivity and specificity. They are the In-
clusive, Etiologic, Substitutive and Exclusive mo-
dels (Table 3) [41]. DSM-IV-TR simplifies this is-
sue to a degree by recommending ‘Count all
physical symptoms unless they are clearly and ful-
ly accounted for by the physical illness’.
For the busy clinician, the bottom line is that one
or both of the following must be present to make the
diagnosis of major depression: depressed mood or
anhedonia (lack of, or diminished, capacity to enjoy).
If one or both of these symptoms are present, then
look for other symptoms to make the diagnosis.
Recognition of major depression can be com-
plicated by vague physical complaints, which can be
the presenting feature. The greater the number of
vague physical complaints, the greater the chances
a mood disorder exists. For example, with four to
Table 1. Diagnostic criteria for major depression
[DSM-IV-TR. American Psychiatric Association,
Washington, DC 2000].
≥ 5 symptoms in the same two-week period
Sleep: insomnia or hypersomnia
Interest: depressed mood*, loss of interest or
pleasure*
Guilt: feelings of worthlessness
Energy: fatigue
Concentration: diminished ability to think or
make decisions
Appetite: weight change
Psychomotor: psychomotor retardation or agitation
Suicidality: preoccupation with death, hopelessness
*Must include 1 of these
Table 2. Complexities of assessment.
Complexity #1 (stigma)
‘Fallacy of good reasons’
— ‘I have good reasons to be depressed…’
— ‘who wouldn’t be depressed? I would be, too’
Complexity #2 (multi-determined symptoms)
‘Confound of overlapping etiologies’
— signs/sxs may be caused by depression,
co-morbid physical illness, or both:
• fatigue/low energy
• loss of appetite
• trouble sleeping
• slowing of motor movements
Table 3. Confound of overlapping etiology diagnostic models [Cohen-Cole and Stoudemire Psychiatric
Clinics of North America 1987].
Model Projected Pos/Neg
Inclusive Count all symptoms regardless of etiology High sensitivity
Low specificity
Etiologic If ‘etiology’ is physical, do not count High face validity
? Inter-rater reliability
Substitutive Substitute physical sxs with psychological sxs ?
Exclusive Exclude common physical symptoms High specificity
Low sensitivity
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five physical symptoms, there is an approximate
20% chance that the patient has depression. When
there are nine or more physical complaints, the
chance is about 60% (Fig. 1) [42].
When patients present with depressive symp-
toms, it is important to consider whether the de-
pression is part of bipolar disorder. In bipolar disor-
der, patients have a history of episodes not only of
depression, but also of mania. This is important
when using antidepressants because their use can
precipitate hypomania or mania in bipolar patients.
It is also important to consider the possibility that
medical problems can mimic depression. Symptoms
often seen in depression, such as trouble sleeping,
low energy or fatigue, loss of appetite, or slowing
of motor movements, can also be seen in medical
conditions. One of the common mimics is hypothy-
roidism. Clinicians should routinely check a thyro-
id stimulating hormone (TSH) level (Fig. 2). Other
medical mimics are extensive and beyond the sco-
pe of this paper [43].
The use of a screening tool can facilitate the
diagnosis of depression. Self-report instruments can
easily be given to patients in the waiting room. In
fact, the use of self-report questionnaires given in
waiting rooms may be the preferred method for
screening [44]. One tool that may be helpful to the
busy clinician is the PHQ-9, mentioned in the case
vignette. This self-rating form for depression can
be completed by patients in a few minutes, and
scored easily and quickly by clinicians (Fig. 3).
Steve’s clinical history and PHQ-9 score cle-
arly indicate he has a severe depression, and
needs treatment. Antidepressants are warranted as
part of the treatment, and can be started in the car-
diologist’s office. The patient should also be refer-
red for psychiatric consultation.
Treatment
Antidepressants
There are many classes of antidepressants
(Table 4) based upon molecular structure and me-
chanism of action. These include the selective
serotonin reuptake inhibitors (SSRIs), serotonin
norepinephrine reuptake inhibitors (SNRIs), the
Norepinephrine and Specific Serotonin Antide-
pressant (NaSSA) mirtazapine, the dopamine
norepinephrine reuptake inhibitor (DNRI) bupro-
pion, monoamine oxidase inhibitors (MAOIs) and
tricyclic antidepressants (TCAs). The first factor
to consider in choosing which antidepressant to
use is safety. The treatment of depression in car-
diac patients, and especially post-MI patients, was
an area of particular concern in the era of tricyclic
antidepressants. However, this changed with the
advent of the SSRIs. SSRIs can generally be used
safely in cardiac patients; howerer see below re-
garding drug–drug interactions to be considered.
Glassman et al. [45] studied the SSRI sertraline in
post-MI or unstable angina patients. The study
found that sertraline was safe and effective in the
treatment of depression in this group. It was not
powered enough to determine if treatment of de-
pression made a statistical difference in cardiac
outcome post-MI or unstable angina (Table 5).
Side effects are also part of the selection pro-
cess. The SSRIs are relatively well-tolerated.
Figure 1. Multiple physical symptoms may indicate de-
pression. *Physical symptoms included fatigue; distur-
bed sleep; menstrual problems; dizziness; GI compla-
ints (nausea, vomiting, gas, constipation, diarrhea); he-
adache; joint or limb pain; back pain; abdominal pain;
chest pain; sexual dysfunction/apathy; and others
[Kroenke K et al. Arch Fam Med, 1994; 3: 774–779].
Figure 2. Signs and symptoms of hypothyroidism and
depression [Extein I, Gold MS eds. Medical Mimics of
Psychiatric Disorders  Progress in Psychiatry, American
Psychiatric Press 1986; 101].
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PATIENT HEALTH QUESTIONNAIRE (PHQ-9)
NAME: _____________________________________________________________________ DATE:_____________________
Over the last 2 weeks, how often have you been bothered by any of the following problems?
(use “” to indicate your answer)
Not at all Several More than Nearly every
days half the days day
1. Little interest or pleasure in doing things 0 1 2 3
2. Feeling down, depressed, or hopeless 0 1 2 3
3. Trouble falling or staying asleep, 0 1 2 3
or sleeping too much
4. Feeling tired or having little energy 0 1 2 3
5. Poor appetite or overeating 0 1 2 3
6. Feeling bad about yourself — or that 0 1 2 3
you are a failure or have let yourself
or your family down
7. Trouble concentrating on things,
such as reading the newspaper 0 1 2 3
or watching television
8. Moving or speaking so slowly that other 0 1 2 3
people could have noticed. Or the opposite
— being so fidgety or restless that you have
been moving around a lot more than usual
9. Thoughts that you would be better off dead, 0 1 2 3
or of hurting yourself in some way
Add columns: +  +
TOTAL:(Healthcare professional: For interpretation of TOTAL,
please refer to accompanying scoring card.)
Not difficult at all ________
Somewhat difficult ________
Very difficult ________
Extremely difficult ________
10. If you checked off any problems, how difficult have
these problems made it for you to do your work, take
care of things at home, or get along with other people?
PHQ-9 is adapted from PRIME MD TODAY, developed by Drs Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke, and colleagues, with an educational
grant from Pfizer Inc. For research information, contact Dr Spitzer at rls8@columbia.edu. Use of the PHQ-9 may only be made in accordance with the
Terms of Use available at http://www.pfizer.com. Copyright ©1999 Pfizer Inc. All rights reserved. PRIME MD TODAY is a trademark of Pfizer Inc.
[ZT242043]
A
Figure 3. Patient health questionnaire (PHQ-9) (A) and instructions for use (B).
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Fold back this page before administering this questionnaire
INSTRUCTIONS FOR USE
for doctor or healthcare professional use only
PHQ−9 QUICK DEPRESSION ASSESSMENT
For initial diagnosis:
1. Patient completes PHQ−9 Quick Depression Assessment on accompanying tear−off pad.
2. If there are at least 4 s in the blue highlighted section (including Questions #1 and #2),
consider a depressive disorder. Add score to determine severity.
3. Consider Major Depressive Disorder
— if there are at least 5 s in the blue highlighted section (one of which corresponds to Question #1 or #2)
Consider Other Depressive Disorder
— if there are 2 to 4 s in the blue highlighted section (one of which corresponds to Question #1 or #2)
Note: Since the questionnaire relies on patient self−report, all responses should be verified by the clinician and a definitive diagnosis made on
clinical grounds, taking into account how well the patient understood the questionnaire, as well as other relevant information from the patient.
Diagnoses of Major Depressive Disorder or Other Depressive Disorder also require impairment of social, occupational, or other important areas
of functioning (Question #10) and ruling out normal bereavement, a history of a Manic Episode (Bipolar Disorder), and a physical disorder,
medication, or other drug as the biological cause of the depressive symptoms.
To monitor severity over time for newly diagnosed patients
or patients in current treatment for depression:
1. Patients may complete questionnaires at baseline and at regular intervals (eg, every 2 weeks)
at home and bring them in at their next appointment for scoring or they may complete the
questionnaire during each scheduled appointment.
2. Add up s by column. For every : Several days = 1    More than half the days = 2    Nearly every day = 3
3. Add together column scores to get a TOTAL score.
4. Refer to the accompanying PHQ-9 Scoring Card to interpret the TOTAL score.
5. Results may be included in patients’ files to assist you in setting up a treatment goal, determining
degree of response, as well as guiding treatment intervention.
PHQ−9 SCORING CARD FOR SEVERITY DETERMINATION
for healthcare professional use only
Scoring — add up all checked boxes on PHQ−9
For every : Not at all = 0; Several days = 1;
More than half the days = 2; Nearly every day = 3
Interpretation of Total Score
Total Score Depression Severity
1–4 Minimal depression
5–9 Mild depression
10–14 Moderate depression
15–19 Moderately severe depression
20–27 Severe depression
Figure 3. Patient health questionnaire (PHQ-9) (A) and instructions for use (B).
B
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Among the more commonly reported side effects
are nausea, diarrhea, constipation, lethargy, activa-
tion, headache and sexual side effects. The antide-
pressant classes that effect norepinephrine have
a small risk of increasing blood pressure. However,
in most cases the effectiveness of these drugs in
the treatment of depression far outweighs the po-
ssibility of increased blood pressure. Should that
occur, and the patient is already on antihypertensi-
ve medication, the blood pressure increase may be
handled simply by adjusting those medications.
Monoamine oxidase inhibitors are excellent medi-
cations for the treatment of depression, but have
strong logistical limitations. Oral forms in the Uni-
ted States require dietary limitations of tyramine
to prevent acute hypertensive reactions. MAOIs
also have the risk of hypertensive crisis if patients
use sympathomimetic drugs like decongestants.
The most common side effect of MAOIs is hypoten-
sion. The relatively new MAOI, the selegiline skin
patch, avoids the need for dietary tyramine restric-
tion at low dose, but carries the same risks as the
oral forms regarding drug-drug interactions of hyper-
tensive crisis or serotonin syndrome. The serotonin
syndrome is a condition of excessive serotonin
action manifested by a wide variety of findings that
can include tachycardia, shivering, diaphoresis, my-
driasis, myoclonus, overreactive reflexes, hyperten-
sion, hyperthermia, agitation and hypervigilance.
The selection of antidepressants should also
take into consideration drug-drug interaction (DDI)
risks. Some of the SSRIs can inhibit P450 isoenzy-
me systems, whereas others are far less likely to.
(Tables 6, 7). For example, although fluoxetine and
paroxetine may be effective antidepressants, they
are potent inhibitors of multiple P450 isoenzyme
systems and could elevate serum levels of beta bloc-
kers and warfarin above what would be expected for
the oral dose given. In this era of multiple specia-
list care, with the potential for multiple handoffs of
patient care, initial safe selection of an antidepres-
sant is important.
The mechanism of action of the antidepressants
can also somewhat guide the selection of medica-
tion. While all antidepressants can theoretically
improve or remit the entire constellation of depres-
sive symptoms, these different mechanisms of ac-
tion might preferentially impact certain symptoms
more than others. For example, the patient with
significant problems with energy, motivation and
drive may do well with the DNRI bupropion or an
SNRI such as venlafaxine; patients with anxiety, im-
pulsivity and aggression could perhaps do better
with an SSRI (Fig. 4).
Knowledge of how the different antidepres-
sants work on the neurophysiology (Table 8) also
helps inform selection, especially of second or third
choice antidepressants. For example, it does not
make clinical sense to use a third SSRI antidepres-
sant if two thus far have not been helpful. Know-
ledge of the mechanisms of action can be important
in treatment-resistant cases that have not had
Table 4. Antidepressants.
TCA SNRI SSRI 5HT-2 DNRI MAOI NaSSA
Antag
Amitriptyline Venlafaxine Fluoxetine Trazodone Bupropion Tranylcypromine Mirtazapine
Nortriptyline (IR/XR) Sertraline Nefazodone (IR, SR, XL) Phenelzine
Desipramine Duloxetine Paroxetine Isocarboxazid
Imipramine Citalopram
Fluvoxamine
Escitalopram
Table 5. Antidepressant safety [SADHART Trial, Glassman et al. 2002].
369 patients with major depression after myocardial infarction or unstable angina
— randomized to sertraline 50–200 mg, or placebo.
Primary goal was to assess safety.
Secondary goal was to assess effect on cardiac outcomes.
Not powered to adequately test effect on morbidity or mortality (7 deaths occurred in the follow-up period).
However, sertraline in absolute numerical terms was superior to placebo in rate of recurrent myocardial
infarction, mortality, heart failure, and angina. Suggested need for larger study.
At least sertraline safe and effective in treatment of depression post-myocardial infarction.
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Table 6. P 450 Isoenzyme inhibition.
3A4 2D6 2C19 2C9 1A2
Escitalopram 0 0 0 0 0
Citalopram 0 X 0 0 X
Sertraline X X XX X  X
Paroxetine X XXX X X X
Fluoxetine XX XXX XX XX X
Fluvoxamine XXX 0 XXX 0 XXX
Venlafaxine 0 X 0 0 0
Mirtazapine X X 0 0 0
Duloxetine 0 XX 0? 0 0/X
Desvenlafaxine 0 0 0 0 0
Bupropion 0 XXX 0 0 0
Nefazodone XXX 0 0 0 0
X — low, XX — moderate, XXX — strong
Table 7. Metabolic pathways of some common medications.
3A4 3A4 2D6 2C19 2C9 1A2
Dextromethorphan Diltiazem Codeine Lansoprazole Diclofenac Amitriptyline
Erythromycin Nifedipine Dextrometh Omeprazole Ibuprofen Imipramine
orphan
Haloperidol Verapamil Desipramine Rabeprazole Naproxen Clomipramine
Imipramine Indinavir Perphenazine
Methadone Risperidone
Prednisone Nelfinavir
Sertraline Ritonavir Nortriptyline Citalopram Piroxicam Clozapine
Tamoxifen Saquinavir Fluoxetine Diazepam Tolbutamide Caffeine
Alprazolam Carbamazepine Fluvoxamine Imipramine Amitriptyline Cyclobenzaprine
Timolol
Diazepam Cisapride Venlafaxine Mephenytoin Celcoxib Estradiol
Midazolam Citalopram Propranolol R-warfarin Fluoxetine Haloperidol
Metoprolol
Triazolam Clomipramine Thioridazine Phenytoin Acetaminophen
Amiodarone Clonazepam Tramadol   Sulfamethoxazole Propranolol   
Cyclobenzaprine Captopril   Tamoxifen Theophylline   
Cyclosporine Mexiletine   S-warfarin  
adequate results often with multiple antidepres-
sants with or without augmentation strategies.
The cost of medications is playing an increasin-
gly important role for patients. Generic forms often
have substantially lower co-pays. This of course
varies by insurance carrier. Since many patients
need to remain on antidepressants for long periods
of time, cost factors to the patient will greatly af-
fect compliance, and hence need to be a factor in
the medication choice.
SSRIs are considered typical first-line antide-
pressants in depressed cardiac patients. Among
them, good options include sertraline or citalopram,
both of which have favorable side effect and DDI
profiles, and also have generic forms. Escitalopram
can also be used, having a favorable side effect and
drug-drug interaction profile but it currently does
not have a generic equivalent. While mild levels of
depression can respond favorably to non-medication
interventions such as counseling, moderate to se-
vere forms of depression are best treated with an-
tidepressants; psychotherapy alone will not be suf-
ficient. However, the addition of psychotherapy can
further improve response rates.
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Steve’s severe major depression warrants use
of an antidepressant and referral for psychotherapy.
Steve’s cardiologist referred him quickly to the
consulting mental health team. The consulting psy-
chiatrist assessed his case and determined that ser-
traline was a reasonable choice. Antidepressants
should be initiated promptly for two reasons: the
full onset of action in major depression is typically
four to six weeks; and the greatest impact of de-
pression on the cardiac patient is within several
weeks after the acute MI. The patient was started
on sertraline 50 mg, and was increased in two
25 mg increments each over a week to a total daily
dose of 100 mg. The consulting psychiatrist referred
Steve back to the cardiologist for ongoing medication
management, and also made a referral for the patient
for psychotherapy. The consulting psychiatrist
remained available to the cardiologist as needed and
also saw the patient four and eight weeks after star-
ting the sertraline to assess medication tolerability
and to monitor symptoms.
Most guidelines recommend a duration of an-
tidepressant use of about a year. This covers the
acute phase, which is approximately 12 weeks when
symptoms typically go into remission, and the con-
tinuation phase, approximately the next six to nine
months when the major depressive episode is con-
sidered recovered. Discontinuing the antidepres-
sant too soon risks symptoms returning before the
depressive episode is fully treated. At the point of
recovery, it is necessary to decide whether to ta-
per off slowly over weeks to months and watch for
signs of relapse or to continue longer. The consul-
ting psychiatrist will take into consideration whe-
ther this is a first episode or a recurrent one, the
severity of the symptoms, the nature of the patient’s
circumstances, and the patient’s awareness of si-
gns of relapse, all of which can impact the decision
of how long to use the antidepressant. Patients with
three or more previous depressive episodes sho-
uld remain on antidepressants indefinitely.
When the time comes to discontinue the anti-
depressant, patients fare better when medication is
tapered off. Patients who stop antidepressants
abruptly risk acute SSRI Discontinuation Syndrome.
This is a syndrome of acute depletion of serotonin
in the synapse brought about when the serotonin
reuptake inhibition is abruptly stopped, causing the
flow of neurotransmitter, in this case serotonin, into
the presynaptic cell, depleting the synapse of neuro-
transmitter (Fig. 5). Symptoms can include severe flu-
like symptoms: headache, diarrhea, dizziness, chills,
nausea, vomiting and fatigue. There may be insom-
nia, agitation, impaired concentration, vivid dreams,
depersonalization, irritability and suicidal ideation.
These symptoms can persist for up to three weeks.
Table 8. Clinically significant consequences of stimulating post-synaptic neurotransmitter receptors.
5 HT 1D 5 HT 1A 5 HT 2 5 HT 3
Antimigraine actions Antidepressant actions Agitation Nausea
Anti-obsessive compulsive Akathisia Gastrointestinal distress
properties Anxiety Diarrhea
Anti-panic and anti-social Panic attacks Headache
phobia properties Insomnia
Anti-bulimia properties Sexual dysfunction
Figure 4. Several neurotransmitters are involved in re-
gulating mood [Stahl SM. Essential psychopharmaco-
logy: Neuroscientific basis and practical applications.
2nd Ed. Cambridge University Press, Cambridge, UK
2000; 152].
Figure 5. Neurotransmitters: mechanism of action [Ne-
meroff CB. Sci Am, 1998; 43–49 (with sub-site addendum)].
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In addition to the risk of the discontinuation
syndrome, abruptly stopping the antidepressant
poses a greater risk of relapse of depression, by not
allowing the brain to readjust to neural mechanisms
affected by the drug. At times, it can be difficult to
distinguish SSRI Discontinuation Syndrome from
a recurrence of depression. A clinically useful way to
do so is to reinstitute the antidepressant. If the pa-
tient’s symptoms remit in hours, up to a day or two,
it is likely to be SSRI Discontinuation Syndrome. If
it takes several days or even weeks to get better,
it is probably a true recurrence of depression.
Individual counseling/therapy
Research suggests it is important for the ini-
tial mental health (MH) referral to be made
quickly, especially after MI, as depression appears
to have the greatest negative impact on the cardiac
patient within weeks of the acute event [46]. Addi-
tionally, during the initial critical period, the pa-
tient’s treating MH team has the best opportunity
to engage the patient and establish a strong con-
nection.
In Steve’s initial therapy session, special atten-
tion was paid to his emotional and cognitive symp-
toms. Research has shown that patients meeting the
criteria for major depression based on emotional/
/cognitive symptoms alone were at greater risk of
mortality compared to those meeting diagnostic
criteria based on somatic symptoms [46, 47].
Feelings of hopelessness are associated with risk
of fatal and nonfatal cardiac events [48] and predict
later CHD mortality in initially healthy individuals
[49]. Steve was provided with the rationale for co-
gnitive-behavioral treatment (CBT), a specific form
of psychotherapy found to be highly efficacious in
the treatment of depression. The Enhancing Reco-
very in Coronary Heart Disease (ENRICHD) trial,
funded by the National Heart Lung and Blood In-
stitute (NHLBI), found that up to six months of in-
dividual CBT (with up to three months of group
therapy where feasible) significantly reduced
depressive symptoms in patients versus a care-
-as-usual group [50]. Additionally, a recent meta-
-analysis on psychological treatment of cardiac patients
found that adding treatment such as CBT to usual care
reduced mortality in patients for at least the first two
years [51]. Benefits were greater for men than for
women. Individual therapy can help patients adhe-
re to treatment recommended by the cardiac team
and increase maintenance of healthy behaviors
to reduce future risk. Steve was made aware that
psychotherapy with patient’s post-MI can be chal-
lenging. This is because a key component of treat-
ment for depression is often behavioral activation,
which involves getting patients to engage in activi-
ties that get them moving and have previously
brought them joy or satisfaction, such as exercise.
It was important that Steve agreed to be upfront abo-
ut his limitations and for the clinician to discuss re-
commendations with his cardiologist to determine
appropriate activity levels. Other elements of CBT
were then explained to Steve, including the assign-
ment of homework to encourage the continuation of
treatment outside of sessions [52]. Steve was infor-
med that treatment would involve approximately
15 weekly sessions, with follow-ups as appropriate.
The treatment would utilize three main techniques:
1) behavioral activation, within the confines of acti-
vity restrictions post-MI; 2) active problem-solving
to improve skill deficits, such as interpersonal com-
munication and coping with stress; and 3) cognitive
restructuring to challenge negative thoughts that
may be maintaining depression and poor self-care.
At the start of each psychotherapy session,
Steve completed a measure of depressive symp-
toms and reported any change in mood or activity
over the past week. Steve and his therapist revie-
wed the previous session and went over any
questions. Homework was reviewed, such as we-
ekly activity logs, thought records and readings. To-
gether, they then set the session’s agenda and prio-
ritized agenda items. The next steps involved
tackling the agenda items, assigning new home-
work, and recapping the session. Steve and his the-
rapist worked on building a strong rapport, which
helped engage Steve in treatment and reinforced
his completion of homework on time. Several tech-
niques were applied to build skills and reduce
depressive symptoms. These included:
— role playing;
— self monitoring;
— behavior chains to reduce risky behaviors;
— challenging negative thoughts about self,
world, and the future;
— identifying negative automatic thoughts that
give rise to feelings of depression and exami-
ning evidence for and against those thoughts
and providing ways to reframe them into posi-
tive thoughts;
— relaxation training to reduce stress and
anxiety;
— assertiveness training to increase ability to
express anger and irritability in a healthy,
productive way;
— active problem solving.
Feedback was provided every few weeks to
Steve’s referring cardiologist.
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At the end of 15 sessions, Steve reached his
goals of reporting a significant reduction in symp-
toms, a significantly lower PHQ-9 score, re-enga-
ging in activities and reporting increased pleasure
in those activities, and following a healthier diet.
Collateral information from his wife was helpful in
knowing his irritability at home decreased and he
was able to communicate more effectively. A relapse
prevention plan was made, in which Steve listed
triggers for negative mood (e.g. decreased sociali-
zation, increased stress at work) and the coping
strategies implemented during the course of treat-
ment that he found effective. Steve was encoura-
ged to schedule a follow-up appointment in three
months. Red flag symptoms i.e. those that would
herald recurrence of the depression, were identi-
fied. Steve expressed an understanding of his high
risk symptoms, and that if they returned, he sho-
uld resume therapy.
Mindfulness-based group therapy
A timely and targeted mindfulness-based
group therapy is another intervention that can be
of value for Steve’s presenting symptoms of hope-
lessness, irritability, and his report of experiencing
high levels of stress.
Mindfulness-based treatment practices have
been a significant innovation in Western health care
since the 1970s. One of the first scientific papers
describing mindfulness was co-authored by the car-
diologist, Herbert Benson MD [53]. Benson follo-
wed this with his book entitled The Relaxation
Response [54]. Fellow New Englander Jon Kabat-
Zinn PhD established the Center for Mindfulness
in 1979 at the University of Massachusetts Medi-
cal Center. He described the practice of Mindful-
ness Based Stress Reduction (MBSR), which has
subsequently been extensively reviewed [55].
Kabat-Zinn says: “Mindfulness means paying attention
in a particular way: on purpose, in the present mo-
ment, and non-judgmentally.” Such an intentional
wakeful state is experienced in a variety of mind-
fulness meditation practices that are taught to pa-
tients. Steve can be taught a systematic way of ob-
serving his own affect, stepping back so that his
emotions do not ‘hijack’ his brain. Instead of beco-
ming a human pressure cooker, unable to delegate,
unable to express his anger without escalating and
yelling, Steve can learn to accept the moment as it
is, with a minimum of harsh self-judgment, which
in turn can allow him to use newly learned beha-
vioral skills to communicate and problem-solve the
issues at hand.
Whether Steve knows it or not, newly learned
behavioral changes result in a helpful feedback loop
of experience, changing the brain even as the brain
changes the experience.
Findings in this area of mind-body/body-mind
work highlight the neuroplasticity and neurogene-
sis capabilities of the brain. Significant increases in
left frontal brain activation have been demonstra-
ted with mindfulness training. This shift in brain
activity is a pattern associated with positive affect
[56]. Such increases in neural activity have the po-
tential to create new synaptic connections. Rese-
arch reveals that experience may stimulate the
growth of new neurons [57].
Mental health theorists and practitioners in the
1980s and 1990s began to combine CBT interven-
tions with the well-documented benefits of Kabat-
Zinn’s work in Mindfulness Based Stress Reduc-
tion. Marsha Linehan PhD developed dialectic
behavior therapy [58]. Dialectic behavior therapy
is a skills-based CBT model that incorporates brief
practices of mindfulness. This approach has been
helpful particularly with a population of patients who
struggle with rapidly shifting affect, feelings of aban-
donment and who present at high risk for self harm
behaviors. Zindel Segal and others have created the
approach known as mindfulness based cognitive
therapy, particularly for patients who have had more
than three episodes of depression and are now in
remission [59]. Steven Hayes and others have de-
veloped an approach to therapy referred to as ac-
ceptance and commitment therapy [60].
One of the common denominators in these va-
rious applications of CBT and mindfulness is the
importance of accepting the present moment for
what it is, even with its problems. In this case, Steve
can learn that his experience of hopelessness, low
self esteem, anger or whatever distress he expe-
riences exists in just this moment, a moment that
then continually changes. As Steve improves his
ability to accept the present moment, he is simul-
taneously better able to move toward change,
similar to the pitcher in an important baseball game
who walks in the tying run, and who can accept the
reality of this unwanted event, is able to let it go
and be ready for the next pitch.
A beneficial way of teaching mindfulness and
CBT skills is to use the modality of a time-limited
structured group therapy setting. In such a group
of six to 12 patients, meetings are held weekly for
several weeks. Patients focus on individually defi-
ned goals. Daily home practice of skills is encoura-
ged between sessions. The group also offers the
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benefits of social support and social acceptance.
Being with others who are also managing the chal-
lenges of illness can normalize one’s experience of
emotional pain, cardiac disease and other illness.
This is a well known effect in group psychothera-
py. Humans are constitutionally built as relational
beings, and are profoundly affected by the experience
of relationship. Woody Allen was not alone in de-
scribing our need for relationship [61]. With the
exquisite intimacy of experience changing the
brain, we are beginning to understand the deep na-
ture of how relationships shape our lives and brains.
This has led some researchers to describe an interdi-
sciplinary field of interpersonal neurobiology [57].
Emotional health depends in many ways on the
presence of community (which can be present in
group therapy), one’s ability to use the power of
thoughts to effect mood and behavior (cognitive
therapy), how we subsequently act (behavior the-
rapy) and being able to ‘stop and smell the roses’,
or at least notice from time to time that there are
roses right in front of us (mindfulness).
Collaborative care for cardiac patients
It is vitally important to address the psychia-
tric issues in the course of treating patients with
heart disease. While cardiologists can, and routinely
do, address some of these issues, the availability of
a consultation psychiatrist or mental health practi-
tioner can provide expertise in the care of these
patients. Collaborative care between medical pro-
viders and psychiatric providers is well known to
result in better patient outcomes. This effect is
particularly important in cardiac patients, given the
link between cardiac outcomes and emotional
issues. Behavioral interventions in patients with
chronic illness can result in better psychosocial out-
comes [62]. Gilbody et al. [63] conducted a meta-
-analysis of 37 randomized control trial studies co-
vering 12,355 patients, and clearly found that
collaborative care for depression produced better
health outcomes, even five years later. The authors
attribute the results to better patient compliance
and the active involvement of MH providers, often
case managers. Katon and Unützer [64] in an
editorial on the Gilbody study emphasize how co-
llaborative care results in better clinical outcomes.
Beyond the clinical outcomes, collaborative care can
be helpful to primary physicians in deciding on the
next steps of antidepressant use or other treatment
strategies, and it can result in neutral or positive
healthcare cost-offset as well [65–67].
Commonly, cardiologists refer to available
mental health clinicians in their local area, subject
to the availability of those clinicians. This is consi-
dered a coordinated relationship. Blount outlines
three types of collaborative care links between
medical physicians and mental health providers
[68]. The coordinated relationship is one in which
providers who practice in different geographical
locations refer patients to one another. This is
a common type of linkage. A second model is that of
co-located care. In this type of link, different specia-
lists work in the same practice setting, for example
within the same office building. This arrangement
reduces the geographical distance and thereby re-
duces some barriers to coordination of care in spe-
cific patient cases. It also helps medical and MH
providers become accustomed to the different ‘cul-
tures’ and ‘languages’ of the different specialties.
The third model is that of integrated healthcare. In
this model, the MH provider is embedded within
the practice of the medical provider. This model has
the benefits of the co-located model plus it further
reduces geographical barriers and greatly enhances
coordination of care. For example, providers can in-
formally consult one another about specific patient
issues regularly. It also increases familiarity and fur-
ther minimizes the specialty-specific cultural differen-
ces, and can minimize patient compliance problems
when cardiologists make mental health referrals.
All models of collaborative care rely on speci-
fic clinicians working with each other. Good colla-
boration requires several key ingredients, among
them a good working relationship between provi-
ders, regular communication and a degree of geo-
graphic proximity [69]. The University of Roche-
ster collaborative care model incorporates ingre-
dients of the coordinated and co-located models.
The outpatient psychiatric consultation program is
located within the University of Rochester Medi-
cal Center, a tertiary care and regional referral fa-
cility. Regulatory and staffing issues limit using an
integrated model at this point, (that is, being in the
same office suite), but the Cardiology and Psychia-
try practices remain within the Medical Center. The
University of Rochester model uses a team of three
specific MH clinicians, a psychiatrist and two men-
tal health clinicians, dedicated to working with the
cardiology practices. This facilitates development
of an interactive treatment team, which in turn en-
hances ongoing collaboration and coordination of
care. In addition to a dedicated team of psychiatric
providers, the psychiatric team uses a dedicated
secretary. In the same way that relationships are
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built between the cardiologists and mental health
providers, the use of a dedicated secretary facilita-
tes coordination between the psychiatry front offi-
ce and front office personnel of the cardiology prac-
tices. This can smooth the referral process and help
resolve communication or coordination issues. The
Department of Psychiatry retains the specialized
mental health insurance and billing functions.
Psychiatrists and MH providers who are certi-
fied or trained in consultation work, or who are com-
fortable dealing with medically ill patients often on
various medications, may offer additional advantages
in collaborative care arrangements. The skills tradi-
tionally important in inpatient consultation/liaison
psychiatry work are also important in outpatient
collaborative care settings: medical-psychiatric dif-
ferential diagnosis, ability to address unexplained
physical symptoms and pain, psychopharmacologi-
cal expertise in medically ill patients and a high
degree of knowledge in secondary psychiatric
disorders [70]. The University of Rochester model
of collaborative care utilizes such MH clinicians.
The University of Rochester model uses a con-
sultative format when seeing patients. This means
referred patients are seen in consultation to the
cardiologists, to whom treatment recommendations
are given. The patients are then referred back to
the cardiologists who provide the ongoing care for
the patients. In this regard, patients are co-mana-
ged. This process ensures the psychiatric clinicians
can remain regularly available to see new patients
promptly, a very important factor for referring car-
diologists. Were the mental health clinicians to fill
their caseloads with patients requiring ongoing
mental health care, there would be little if any time
for new cases, or waiting times for new patients
could be prolonged. When the consulting psychia-
trist identifies referred patients as being in need of
ongoing or more intensive psychiatric care, the
psychiatrist can refer such patients into appropria-
te MH care. Thereafter, the psychiatrist acts as
a liaison as necessary between the cardiologist and
the specialized MH clinicians. This liaison function
offers the cardiologist ease of access to MH infor-
mation about their patients, utilizing their collabo-
rative link with their psychiatric consultant.
Ease of access for the cardiologist is crucial.
We use a dedicated phone number for referrals, gi-
ven only to referring providers. This phone num-
ber is different from the number of the general MH
clinic. Finally, patient-specific communication,
which occurs regularly, involves clinical notes con-
tained in an electronic medical record, and e-mail
and phone contacts between providers.
Summary
The treatment of stress, anxiety and depression
in cardiac patients can improve cardiac outcomes.
Psychotropic medications, including antide-
pressants, have an important place in the treatment
armoury. In addition, CBT and group-based mind-
fulness interventions have a role in treating cardiac
patients and improving cardiac outcomes. The use
of a collaborative model, which maximizes commu-
nication and contact and minimizes geographic
distance between cardiac and psychiatric providers,
can also improve cardiac outcomes and can be of
significant value to cardiologists in managing psy-
chiatric aspects in their patients.
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